Bright Green (BGXX.US): The 2023 Q4 earnings report achieved revenue of $0, with a previous value of $0; earnings per share of -$0.03, with a previous value of -$0.01.
Bright Green (BGXX.US): The 2023 Q4 earnings report achieved revenue of $0, with a previous value of $0; earnings per share of -$0.03, with a previous value of -$0.01.
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersOntrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands at $18.9 million. Ocuphire Pharma (NASDAQ:OCUP) stock rose 7.82%
Bright Green Corp. Enhances CEO's Compensation and Incentives
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSalarius Pharmaceuticals (NASDAQ:SLRX) shares rose 33.9% to $0.83 during Friday's after-market session. The market value of their outstanding shares is at $3.2 million. Masimo (NASDAQ:MASI) sha
Bright Green to Install 102-megawatt Solar Power Generation Field
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million. Nuvectis Pharma (NASDAQ:NVCT) stock moved
BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.
GRANTS, NEW MEXICO, March 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") Today announced that BGXX will install a 102-megawatt solar field to power the electricity
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersMolina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. Evoke Pharma (NASDAQ:EVOK) shares
Regulus Phase 1 Data; Bright Green BGXX Agreement
Trending Stocks Today: Regulus Therapeutics Shoots up 90.57%
March 12th - US stocks trending in regular trading hours.Gainers: $Regulus Therapeutics(RGLS.US)$ shoots up 90.57% to $2.63 with a turnover of $395.04 million. $ClearOne(CLRO.US)$ soars 110.97% to $1.
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersRegulus Therapeutics (NASDAQ:RGLS) stock increased by 94.9% to $2.69 during Tuesday's regular session. The company's market cap stands at $54.3 million. Bright Green (NASDAQ:BGXX) shares increa
Bright Green to Expand Drug Production Plant With $250 Million Project
By Dean Seal Bright Green has signed a $250 million deal to expand its facility in New Mexico for the production and processing of cannabis and other federally illegal drugs. The company said Tuesda
Bright Green Corp Signed An Agreement With Dalsem Greenhouse Technologies BV For $250M For Expansion Of Its Controlled Substances Drug Production Facility In Grants, New Mexico And Obtained $60M In Financing
Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") today announced that it has signed an agreement with Dalsem Greenhouse Technologies BV for a $250 million construction project to expand the Company's current research, production and extraction processing facility located in rural Grants, New Mexico (the "Dalsem Agreement").
BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING
Bright Green Corporation (Nasdaq: BGXX) today announced that it has signed an agreement with Dalsem Greenhouse Technologies BV for a $250 million construction project to expand the Company's current research, production and extraction processing facility located in rural Grants, New Mexico (the "Dalsem Agreement").
Bright Green Corp Enhances Leadership and Governance
Bright Green Corporation Submits For DEA Registration For Production Of Schedule I And Schedule II Controlled Substances
Bright Green Corporation announced today the submission of its DEA Registration for Bulk Production of Schedule I and Schedule II Controlled Substances.
DEA Clears This NASDAQ-Traded 'Plant-Touching' Firm To Research And Produce Schedule I And II Plant-Based Drugs
Bright Green Corporation (NASDAQ:BGXX) announced on Thursday that it has received final approval from the New Mexico Board of Pharmacy and the DEA to register, license and authorize Schedule I and Sch
Bright Green Shares Up 43% on 'Unique Licensing' for Schedule I and II Drugs
By Josh Beckerman Bright Green shares were recently up 43% to 27 cents Thursday after the company received final approval for "unique licensing" for certain drugs from the New Mexico Board of Pharmac
Bright Green Secures DEA Approval for Drug Research
No Data